The Filing Desk

Phathom Pharmaceuticals vs Stoke Therapeutics

Phathom Pharmaceuticals PHAT · Stoke Therapeutics STOK · Pharmaceuticals

Stoke Therapeutics reported revenue of $184 million in fiscal 2025, about the same as Phathom Pharmaceuticals' $175 million in fiscal 2025. Phathom Pharmaceuticals' revenue grew 216.9% in its latest year, and Stoke Therapeutics' grew 404.5%. Phathom Pharmaceuticals had an operating margin of -91.4%, against -11.2% at Stoke Therapeutics. Free cash flow was −$167 million at Phathom Pharmaceuticals and $45 million at Stoke Therapeutics.

Side by side

Phathom PharmaceuticalsStoke Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$175M$184M
Revenue growth216.9%404.5%
Revenue growth a year, last 5 years——
Gross margin87.1%—
Operating margin−91.4%−11.2%
Net margin−126.3%−3.7%
Free cash flow−$167M$45M
Free cash flow margin−95.4%24.4%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count15.4%9.7%
Last close$5.08$26.93
P/E at the last close——
Insider trades, last 12 months—sold $7.6 million
Piotroski F-score4 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Phathom PharmaceuticalsStoke Therapeutics
Operating margin
Percent of revenue
Phathom PharmaceuticalsStoke Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Phathom PharmaceuticalsStoke Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Phathom Pharmaceuticals and Stoke Therapeutics pages.